The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 21, 2014

Filed:

Dec. 20, 2010
Applicants:

Robin Callan, Bellevue, WA (US);

James J. Cole, Arlington, WA (US);

Inventors:

Robin Callan, Bellevue, WA (US);

James J. Cole, Arlington, WA (US);

Assignee:

Advanced Renal Technologies, Bellevue, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61M 37/00 (2006.01); A61M 1/36 (2006.01); A61K 33/10 (2006.01); A61K 31/19 (2006.01); A61M 1/16 (2006.01); A61K 33/14 (2006.01); A61K 31/191 (2006.01);
U.S. Cl.
CPC ...
A61M 1/3672 (2013.01); A61K 33/10 (2013.01); A61K 31/19 (2013.01); A61M 1/1654 (2013.01); A61K 33/14 (2013.01); A61K 31/191 (2013.01);
Abstract

The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCOlevel is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCOnormalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.19 to 1.34±0.2 (p=0.01). This increased urea clearance may be the result of the anticoagulant property of citrate maintaining patency of the dialyzer membrane. The increase in pre-dialysis serum HCOmay represent increased delivery from the dialysate and production from citric acid.


Find Patent Forward Citations

Loading…